Investors seeking exposure to cutting-edge life sciences innovation will have a direct line to management teams at the upcoming Life Sciences Virtual Investor Forum, hosted by Virtual Investor Conferences and presented by B2i Digital, Inc., on September 17, 2026. The online event brings together seven companies whose pipelines target some of the most challenging areas in medicine, including photothermal cancer therapy, cannabinoid-based treatments for autoimmune and inflammatory conditions, and precision drug delivery across the blood-brain barrier. With live presentations and Q&A sessions, the forum provides a rare opportunity for investors to assess not just the science but the strategic direction of these firms.
The lineup spans a diverse range of therapeutic approaches. Sona Nanotech Inc. is developing a photothermal cancer therapy built on gold nanorods, a platform that could offer targeted tumor destruction with minimal collateral damage. Raphael Pharmaceutical focuses on cannabinoid-based formulations for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease, tapping into the growing interest in cannabinoid therapeutics. Amplia Therapeutics Ltd. brings a pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis, addressing two areas with significant unmet need. Adaptin Bio, Inc. is advancing precision drug delivery technologies aimed at target tissues, including behind the blood-brain barrier, a longstanding hurdle in treating neurological diseases.
Acurx Pharmaceuticals, Inc. is developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens, a critical effort amid rising antimicrobial resistance. CytoDyn Inc. is studying a humanized monoclonal antibody in solid-tumor oncology, while 4DMedical Ltd. offers FDA-cleared four-dimensional respiratory imaging, a diagnostic tool that could improve early detection and monitoring of lung diseases.
The forum's format—30-minute live sessions followed by audience Q&A—allows investors to probe management on clinical timelines, regulatory pathways, and commercialization strategies. Replays will be available on the B2i Digital and OTC Markets YouTube channels, extending the reach beyond the live event. As David Shapiro, Chief Executive Officer of B2i Digital, Inc., noted, "Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind."
For investors, the implications are significant. The life sciences sector is driven by innovation, and events like this provide early visibility into companies that may be poised for breakthroughs. With B2i Digital's media network spanning over 800 outlets and a combined monthly audience of more than 330 million, the forum amplifies these companies' stories to a vast investor base. Registration is open at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC, and further details on presenting companies are available at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum. As the sector continues to attract capital, forums like this serve as a bridge between promising science and the investors who can fuel its progress.
